CDC Health Advisory Addresses Limited Availability of Nirsevimab

Published: 10/25/2023

  • Centers for Disease Control and Prevention
Relevant To:
  • Urgent Care,
  • Medical Office,
  • Critical Access Hospitals,
  • Hospitals,
  • Pharmacy,
  • Rural Health Clinics

A new Health Advisory from the Centers for Disease Control and Prevention (CDC) provides options for clinicians to protect infants from respiratory syncytial virus (RSV) in the context of a limited supply of nirsevimab, a long-acting monoclonal antibody immunization product recommended for preventing RSV-associated lower respiratory tract disease in infants.

  • In the context of limited supply during the 2023–2024 RSV season, CDC recommends prioritizing available nirsevimab 100mg doses for in

Sign Up for Free Trial